{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:47:05Z","timestamp":1792504025707,"version":"4.5.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11427-025-3193-9","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:43:22Z","timestamp":1773924202000},"page":"1950-1965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome"],"prefix":"10.1007","volume":"69","author":[{"given":"Xiao-Dong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong-Yue","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin-Fen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Chul","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CHAIN Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"3193_CR1","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1093\/eurjpc\/zwab212","volume":"29","author":"L Alon","year":"2022","unstructured":"Alon, L., Corica, B., Raparelli, V., Cangemi, R., Basili, S., Proietti, M., and Romiti, G.F. (2022). Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Prev Cardiol 29, 938\u2013946.","journal-title":"Eur J Prev Cardiol"},{"key":"3193_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S.D., Butler, J., Filippatos, G., Ferreira, J.P., Bocchi, E., B\u00f6hm, M., Brunner-La Rocca, H.P., Choi, D.J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021). Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385, 1451\u20131461.","journal-title":"N Engl J Med"},{"key":"3193_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","volume":"15","author":"QM Anstee","year":"2018","unstructured":"Anstee, Q.M., Mantovani, A., Tilg, H., and Targher, G. (2018). Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 15, 425\u2013439.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3193_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s12916-025-04320-7","volume":"23","author":"VA Arita","year":"2025","unstructured":"Arita, V.A., Cabezas, M.C., Hern\u00e1ndez Vargas, J.A., Trujillo-C\u00e1ceres, S.J., Mendez Pernicone, N., Bridge, L.A., Raeisi-Dehkordi, H., Dietvorst, C.A.W., Dekker, R., Uriza-Pinz\u00f3n, J.P., et al. (2025). Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials. BMC Med 23, 502.","journal-title":"BMC Med"},{"key":"3193_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong, M.J., Gaunt, P., Aithal, G.P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M.A., et al. (2016). Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679\u2013690.","journal-title":"Lancet"},{"key":"3193_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11906-023-01242-8","volume":"25","author":"OO Badmus","year":"2023","unstructured":"Badmus, O.O., Hinds Jr, T.D., and Stec, D.E. (2023). Mechanisms linking metabolic-associated fatty liver disease (MAFLD) to cardiovascular disease. Curr Hypertens Rep 25, 151\u2013162.","journal-title":"Curr Hypertens Rep"},{"key":"3193_CR7","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"C Baigent","year":"2022","unstructured":"Baigent, C., Emberson, J.R., Haynes, R., Herrington, W.G., Judge, P., Landray, M.J., Mayne, K.J., Ng, S.Y.A., Preiss, D., Roddick, A.J., et al. (2022). Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400, 1788\u20131801.","journal-title":"Lancet"},{"key":"3193_CR8","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/apt.17930","volume":"59","author":"SK Bansal","year":"2024","unstructured":"Bansal, S.K., and Bansal, M.B. (2024). Pathogenesis of MASLD and MASH\u2014role of insulin resistance and lipotoxicity. Aliment Pharmacol Ther 59, S10\u2013S22.","journal-title":"Aliment Pharmacol Ther"},{"key":"3193_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/gutjnl-2024-332687","volume":"74","author":"S Bea","year":"2025","unstructured":"Bea, S., Ko, H.Y., Bae, J.H., Cho, Y.M., Chang, Y., Ryu, S., Byrne, C.D., and Shin, J.Y. (2025). Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease. Gut 74, 284\u2013294.","journal-title":"Gut"},{"key":"3193_CR10","doi-asserted-by":"publisher","first-page":"e16159","DOI":"10.1111\/liv.16159","volume":"45","author":"J Bilson","year":"2025","unstructured":"Bilson, J., Hydes, T.J., McDonnell, D., Buchanan, R.M., Scorletti, E., Mantovani, A., Targher, G., and Byrne, C.D. (2025). Impact of metabolic syndrome traits on kidney disease risk in individuals with MASLD: a UK Biobank Study. Liver Int 45, e16159.","journal-title":"Liver Int"},{"key":"3193_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","volume":"2","author":"ML Boland","year":"2020","unstructured":"Boland, M.L., Laker, R.C., Mather, K., Nawrocki, A., Oldham, S., Boland, B.B., Lewis, H., Conway, J., Naylor, J., Guionaud, S., et al. (2020). Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab 2, 413\u2013431.","journal-title":"Nat Metab"},{"key":"3193_CR12","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1042\/CS20240833","volume":"138","author":"S Bott","year":"2024","unstructured":"Bott, S., Lallement, J., Marino, A., Daskalopoulos, E.P., Beauloye, C., Esfahani, H., Dessy, C., and Leclercq, I.A. (2024). When the liver is in poor condition, so is the heart\u2014cardiac remodelling in MASH mouse models. Clin Sci 138, 1151\u20131171.","journal-title":"Clin Sci"},{"key":"3193_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41575-025-01045-z","volume":"22","author":"CD Byrne","year":"2025","unstructured":"Byrne, C.D., Armandi, A., Pellegrinelli, V., Vidal-Puig, A., and Bugianesi, E. (2025). Metabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment. Nat Rev Gastroenterol Hepatol 22, 314\u2013328.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3193_CR14","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne, C.D., and Targher, G. (2015). NAFLD: a multisystem disease. J Hepatol 62, S47\u2013S64.","journal-title":"J Hepatol"},{"key":"3193_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","volume":"72","author":"CD Byrne","year":"2020","unstructured":"Byrne, C.D., and Targher, G. (2020). NAFLD as a driver of chronic kidney disease. J Hepatol 72, 785\u2013801.","journal-title":"J Hepatol"},{"key":"3193_CR16","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/liv.14461","volume":"40","author":"X Cai","year":"2020","unstructured":"Cai, X., Zheng, S., Liu, Y., Zhang, Y., Lu, J., and Huang, Y. (2020). Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation. Liver Int 40, 1594\u20131600.","journal-title":"Liver Int"},{"key":"3193_CR17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.cgh.2023.09.018","volume":"22","author":"KE Chan","year":"2024","unstructured":"Chan, K.E., Ong, E.Y.H., Chung, C.H., Ong, C.E.Y., Koh, B., Tan, D.J.H., Lim, W.H., Yong, J.N., Xiao, J., Wong, Z.Y., et al. (2024). Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of 129 studies. Clin Gastroenterol Hepatol 22, 488\u2013498.e14.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3193_CR18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cgh.2024.09.041","volume":"23","author":"M Cheraghpour","year":"2025","unstructured":"Cheraghpour, M., Hatami, B., and Singal, A.G. (2025). Lifestyle and pharmacologic approaches to prevention of metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma. Clin Gastroenterol Hepatol 23, 685\u2013694.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3193_CR19","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","volume":"142","author":"F Cosentino","year":"2020","unstructured":"Cosentino, F., Cannon, C.P., Cherney, D.Z.I., Masiukiewicz, U., Pratley, R., Dagogo-Jack, S., Frederich, R., Charbonnel, B., Mancuso, J., Shih, W.J., et al. (2020). Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease. Circulation 142, 2205\u20132215.","journal-title":"Circulation"},{"key":"3193_CR20","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","volume":"34","author":"T Coskun","year":"2022","unstructured":"Coskun, T., Urva, S., Roell, W.C., Qu, H., Loghin, C., Moyers, J.S., O\u2019Farrell, L.S., Briere, D.A., Sloop, K.W., Thomas, M.K., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab 34, 1234\u20131247.e9.","journal-title":"Cell Metab"},{"key":"3193_CR21","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi, K., Abdelmalek, M.F., Apovian, C.M., Balapattabi, K., Bannuru, R.R., Barb, D., Bardsley, J.K., Beverly, E.A., Corbin, K.D., ElSayed, N.A., et al. (2025). Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care 48, 1057\u20131082.","journal-title":"Diabetes Care"},{"key":"3193_CR22","doi-asserted-by":"publisher","first-page":"156306","DOI":"10.1016\/j.metabol.2025.156306","volume":"170","author":"DJ Cuthbertson","year":"2025","unstructured":"Cuthbertson, D.J., Kennedy, O.J., Bilson, J., Hydes, T.J., Targher, G., Glyn-Owen, K., Buchanan, R., Roderick, P., and Byrne, C.D. (2025). Impact of metabolic dysfunction severity in steatotic liver disease and its interaction with liver fibrosis on all-cause mortality and multiple hepatic and extra-hepatic outcomes. Metabolism 170, 156306.","journal-title":"Metabolism"},{"key":"3193_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.tem.2025.01.002","volume":"36","author":"S Daniels","year":"2025","unstructured":"Daniels, S., Karlsson, C., Schrauwen, P., and Parker, V.E.R. (2025). Glucagon-like peptide-1 receptor agonism and end-organ protection. Trends Endocrinol Metab 36, 301\u2013315.","journal-title":"Trends Endocrinol Metab"},{"key":"3193_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2337\/dc14-2883","volume":"39","author":"MJ Davies","year":"2016","unstructured":"Davies, M.J., Bain, S.C., Atkin, S.L., Rossing, P., Scott, D., Shamkhalova, M.S., Bosch-Traberg, H., Syr\u00e9n, A., and Umpierrez, G.E. (2016). Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care 39, 222\u2013230.","journal-title":"Diabetes Care"},{"key":"3193_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/HEP.0000000000000735","volume":"82","author":"S Driessen","year":"2025","unstructured":"Driessen, S., Francque, S.M., Anker, S.D., Castro Cabezas, M., Grobbee, D.E., Tushuizen, M.E., and Holleboom, A.G. (2025). Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatology 82, 487\u2013503.","journal-title":"Hepatology"},{"key":"3193_CR26","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1136\/gutjnl-2021-326874","volume":"71","author":"JF Dufour","year":"2022","unstructured":"Dufour, J.F., Anstee, Q.M., Bugianesi, E., Harrison, S., Loomba, R., Paradis, V., Tilg, H., Wong, V.W.S., and Zelber-sagi, S. (2022). Current therapies and new developments in NASH. Gut 71, 2123\u20132134.","journal-title":"Gut"},{"key":"3193_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1146\/annurev-physiol-022724-105515","volume":"87","author":"M Dukewich","year":"2025","unstructured":"Dukewich, M., Yuan, L., and Terrault, N.A. (2025). At the crossroads of health and disease: consequences of fat in the liver. Annu Rev Physiol 87, 325\u2013352.","journal-title":"Annu Rev Physiol"},{"key":"3193_CR28","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1016\/j.jhep.2024.02.001","volume":"80","author":"X Fan","year":"2024","unstructured":"Fan, X., Zhang, B., Shi, Y., Liu, L., and Zhao, J. (2024). Systemic metabolic abnormalities: key drivers of complications and mortality in MASLD. J Hepatol 80, e246\u2013e248.","journal-title":"J Hepatol"},{"key":"3193_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","volume":"21","author":"G Feng","year":"2024","unstructured":"Feng, G., Valenti, L., Wong, V.W.S., Fouad, Y.M., Yilmaz, Y., Kim, W., Sebastiani, G., Younossi, Z.M., Hernandez-Gea, V., and Zheng, M.H. (2024). Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 21, 46\u201356.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3193_CR30","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s00018-019-03155-9","volume":"76","author":"YL Feng","year":"2019","unstructured":"Feng, Y.L., Cao, G., Chen, D.Q., Vaziri, N.D., Chen, L., Zhang, J., Wang, M., Guo, Y., and Zhao, Y.Y. (2019). Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease. Cell Mol Life Sci 76, 4961\u20134978.","journal-title":"Cell Mol Life Sci"},{"key":"3193_CR31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jchf.2020.02.010","volume":"8","author":"JP Ferreira","year":"2020","unstructured":"Ferreira, J.P., Jhund, P.S., Duarte, K., Claggett, B.L., Solomon, S.D., Pocock, S., Petrie, M.C., Zannad, F., and McMurray, J.J.V. (2020). Use of the win ratio in cardiovascular trials. JACC Heart Fail 8, 441\u2013450.","journal-title":"JACC Heart Fail"},{"key":"3193_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13098-025-01796-4","volume":"17","author":"AF Godoy-Matos","year":"2025","unstructured":"Godoy-Matos, A.F., Val\u00e9rio, C.M., J\u00fanior, W.S.S., de Araujo-Neto, J.M., Sposito, A.C., and Suassuna, J.H.R. (2025). CARDIAL-MS (CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome): a new proposition for an integrated multisystem metabolic disease. Diabetol Metab Syndr 17, 218.","journal-title":"Diabetol Metab Syndr"},{"key":"3193_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S2468-1253(24)00310-8","volume":"10","author":"JJ Gries","year":"2025","unstructured":"Gries, J.J., Lazarus, J.V., Brennan, P.N., Siddiqui, M.S., Targher, G., Lang, C.C., Virani, S.S., Lavie, C.J., Isaacs, S., Arab, J.P., et al. (2025). Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease. Lancet Gastroenterol Hepatol 10, 82\u201394.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3193_CR34","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H.J.L., Stef\u00e1nsson, B.V., Correa-Rotter, R., Chertow, G.M., Greene, T., Hou, F.F., Mann, J.F.E., McMurray, J.J.V., Lindberg, M., Rossing, P., et al. (2020). Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383, 1436\u20131446.","journal-title":"N Engl J Med"},{"key":"3193_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington, W.G., Staplin, N., Wanner, C., Green, J.B., Hauske, S.J., Emberson, J.R., Preiss, D., Judge, P., Mayne, K.J., Ng, S.Y.A., et al. (2023). Empagliflozin in patients with chronic kidney disease. N Engl J Med 388, 117\u2013127.","journal-title":"N Engl J Med"},{"key":"3193_CR36","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1097\/HEP.0000000000001015","volume":"81","author":"DQ Huang","year":"2025","unstructured":"Huang, D.Q., Wilson, L.A., Behling, C., Amangurbanova, M., Kleiner, D.E., Kowdley, K.V., Dasarathy, S., Terrault, N.A., Diehl, A.M., Chalasani, N., et al. (2025a). Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: a prospective multicenter study. Hepatology 81, 1553\u20131563.","journal-title":"Hepatology"},{"key":"3193_CR37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","volume":"165","author":"DQ Huang","year":"2023","unstructured":"Huang, D.Q., Wilson, L.A., Behling, C., Kleiner, D.E., Kowdley, K.V., Dasarathy, S., Amangurbanova, M., Terrault, N.A., Diehl, A.M., Chalasani, N., et al. (2023). Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study. Gastroenterology 165, 463\u2013472.e5.","journal-title":"Gastroenterology"},{"key":"3193_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang, D.Q., Wong, V.W.S., Rinella, M.E., Boursier, J., Lazarus, J.V., Yki-J\u00e4rvinen, H., and Loomba, R. (2025b). Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers 11, 14.","journal-title":"Nat Rev Dis Primers"},{"key":"3193_CR39","doi-asserted-by":"publisher","first-page":"155937","DOI":"10.1016\/j.metabol.2024.155937","volume":"157","author":"M Huttasch","year":"2024","unstructured":"Huttasch, M., Roden, M., and Kahl, S. (2024). Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? Metabolism 157, 155937.","journal-title":"Metabolism"},{"key":"3193_CR40","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/apt.17617","volume":"58","author":"M Jamalinia","year":"2023","unstructured":"Jamalinia, M., Zare, F., and Lankarani, K.B. (2023). Systematic review and meta-analysis: association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease. Aliment Pharmacol Ther 58, 384\u2013394.","journal-title":"Aliment Pharmacol Ther"},{"key":"3193_CR41","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1111\/dom.16568","volume":"27","author":"M Jamalinia","year":"2025","unstructured":"Jamalinia, M., Zare, F., Mantovani, A., Targher, G., and Lonardo, A. (2025). Metabolic dysfunction-associated steatotic liver disease and sex-specific risk of fatal and non-fatal cardiovascular events: a meta-analysis. Diabetes Obes Metab 27, 5171\u20135181.","journal-title":"Diabetes Obes Metab"},{"key":"3193_CR42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/apt.17869","volume":"59","author":"M Jamalinia","year":"2024","unstructured":"Jamalinia, M., Zare, F., Noorizadeh, K., and Bagheri Lankarani, K. (2024). Systematic review with meta-analysis: steatosis severity and subclinical atherosclerosis in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther 59, 445\u2013458.","journal-title":"Aliment Pharmacol Ther"},{"key":"3193_CR43","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","volume":"143","author":"PS Jhund","year":"2021","unstructured":"Jhund, P.S., Solomon, S.D., Docherty, K.F., Heerspink, H.J.L., Anand, I.S., B\u00f6hm, M., Chopra, V., de Boer, R.A., Desai, A.S., Ge, J., et al. (2021). Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation 143, 298\u2013309.","journal-title":"Circulation"},{"key":"3193_CR44","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","volume":"43","author":"S Kahl","year":"2020","unstructured":"Kahl, S., Gancheva, S., Stra\u00dfburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020). Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care 43, 298\u2013305.","journal-title":"Diabetes Care"},{"key":"3193_CR45","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1080\/13543784.2024.2441865","volume":"33","author":"E Kaya","year":"2024","unstructured":"Kaya, E., Yilmaz, Y., and Alkhouri, N. (2024). Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction. Expert Opin Invest Drugs 33, 1167\u20131176.","journal-title":"Expert Opin Invest Drugs"},{"key":"3193_CR46","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1080\/14656566.2025.2566258","volume":"26","author":"E Kaya","year":"2025","unstructured":"Kaya, E., Yilmaz, Y., and Alkhouri, N. (2025). Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs. Expert Opin Pharmacother 26, 1589\u20131598.","journal-title":"Expert Opin Pharmacother"},{"key":"3193_CR47","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s12072-016-9705-x","volume":"10","author":"G Kim","year":"2016","unstructured":"Kim, G., Kim, J., Lim, Y.L., Kim, M.Y., and Baik, S.K. (2016). Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review. Hepatol Int 10, 819\u2013828.","journal-title":"Hepatol Int"},{"key":"3193_CR48","doi-asserted-by":"publisher","first-page":"E833","DOI":"10.1152\/ajpendo.00392.2024","volume":"328","author":"HR Kim","year":"2025","unstructured":"Kim, H.R., Tabiatnejad, P., Arestakesyan, H., and Young, C.N. (2025). Modulation of liver lipid metabolic pathways by central nervous system ER stress. Am J Physiol Endocrinol Metab 328, E833\u2013E844.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3193_CR49","doi-asserted-by":"publisher","first-page":"156081","DOI":"10.1016\/j.metabol.2024.156081","volume":"163","author":"ZA Kipp","year":"2025","unstructured":"Kipp, Z.A., Badmus, O.O., Stec, D.E., Hall, B., and Hinds Jr, T.D. (2025). Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: a biomarker for insulin resistance in the cardiovascular-kidney-metabolic (CKM) syndrome. Metabolism 163, 156081.","journal-title":"Metabolism"},{"key":"3193_CR50","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod, M.N., Abildstr\u00f8m, S.Z., Borlaug, B.A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G.K., Kitzman, D.W., Lindegaard, M.L., M\u00f8ller, D.V., et al. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389, 1069\u20131084.","journal-title":"N Engl J Med"},{"key":"3193_CR51","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod, M.N., Petrie, M.C., Borlaug, B.A., Butler, J., Davies, M.J., Hovingh, G.K., Kitzman, D.W., M\u00f8ller, D.V., Treppendahl, M.B., Verma, S., et al. (2024a). Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 390, 1394\u20131407.","journal-title":"N Engl J Med"},{"key":"3193_CR52","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.jchf.2024.09.004","volume":"12","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod, M.N., Platz, E., Wharton, S., le Roux, C.W., Brueckmann, M., Ajaz Hussain, S., Unseld, A., Startseva, E., and Kaplan, L.M. (2024b). Survodutide for the treatment of obesity: rationale and design of the SYNCHRONIZE cardiovascular outcomes trial. JACC Heart Fail 12, 2101\u20132109.","journal-title":"JACC Heart Fail"},{"key":"3193_CR53","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41423-025-01313-7","volume":"22","author":"E Kostallari","year":"2025","unstructured":"Kostallari, E., Schwabe, R.F., and Guillot, A. (2025). Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells. Cell Mol Immunol 22, 1205\u20131225.","journal-title":"Cell Mol Immunol"},{"key":"3193_CR54","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay, M.S., Krishan, S., Mishra, S.K., Farooqui, K.J., Singh, M.K., Wasir, J.S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H.K., et al. (2018). Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care 41, 1801\u20131808.","journal-title":"Diabetes Care"},{"key":"3193_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cmet.2024.09.009","volume":"37","author":"SM Lam","year":"2025","unstructured":"Lam, S.M., Wang, Z., Song, J.W., Shi, Y., Liu, W.Y., Wan, L.Y., Duan, K., Chua, G.H., Zhou, Y., Wang, G., et al. (2025). Non-invasive lipid panel of MASLD fibrosis transition underscores the role of lipoprotein sulfatides in hepatic immunomodulation. Cell Metab 37, 69\u201386.e7.","journal-title":"Cell Metab"},{"key":"3193_CR56","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","volume":"79","author":"MH Le","year":"2023","unstructured":"Le, M.H., Le, D.M., Baez, T.C., Wu, Y., Ito, T., Lee, E.Y., Lee, K.S., Stave, C.D., Henry, L., Barnett, S.D., et al. (2023). Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol 79, 287\u2013295.","journal-title":"J Hepatol"},{"key":"3193_CR57","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","volume":"12","author":"CW le Roux","year":"2024","unstructured":"le Roux, C.W., Steen, O., Lucas, K.J., Startseva, E., Unseld, A., and Hennige, A.M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 12, 162\u2013173.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3193_CR58","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","volume":"73","author":"HH Lee","year":"2024","unstructured":"Lee, H.H., Lee, H.A., Kim, E.J., Kim, H.Y., Kim, H.C., Ahn, S.H., Lee, H., and Kim, S.U. (2024). Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut 73, 533\u2013540.","journal-title":"Gut"},{"key":"3193_CR59","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1007\/s11427-023-2494-x","volume":"67","author":"S Li","year":"2024","unstructured":"Li, S., Mehal, W.Z., and Ouyang, X. (2024). RNA modifications in the progression of liver diseases: from fatty liver to cancer. Sci China Life Sci 67, 2105\u20132119.","journal-title":"Sci China Life Sci"},{"key":"3193_CR60","doi-asserted-by":"publisher","first-page":"n1091","DOI":"10.1136\/bmj.n1091","volume":"373","author":"S Li","year":"2021","unstructured":"Li, S., Vandvik, P.O., Lytvyn, L., Guyatt, G.H., Palmer, S.C., Rodriguez-Gutierrez, R., Foroutan, F., Agoritsas, T., Siemieniuk, R.A.C., Walsh, M., et al. (2021). SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ 373, n1091.","journal-title":"BMJ"},{"key":"3193_CR61","doi-asserted-by":"publisher","first-page":"100897","DOI":"10.1016\/j.jhepr.2023.100897","volume":"5","author":"W Li","year":"2023","unstructured":"Li, W., Sheridan, D., McPherson, S., Alazawi, W., Abeysekera, K., Marjot, T., Brennan, P., Mahgoub, S., Cacciottolo, T., Hydes, T., et al. (2023). National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022. JHEP Rep 5, 100897.","journal-title":"JHEP Rep"},{"key":"3193_CR62","first-page":"101717","volume":"64","author":"X Li","year":"2025","unstructured":"Li, X., Zhou, X.D., Wu, J., Zhao, Z., Xie, F., Li, Y., Li, W., Yan, X., Sui, S., Zhang, L., et al. (2025). Pediatric MASLD in China: epidemiology, screening, diagnosis, and management. Lancet Reg Health West Pac 64, 101717.","journal-title":"Lancet Reg Health West Pac"},{"key":"3193_CR63","doi-asserted-by":"publisher","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin, J., Huang, Y., Xu, B., Gu, X., Huang, J., Sun, J., Jia, L., He, J., Huang, C., Wei, X., et al. (2025). Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ 389, e083735.","journal-title":"BMJ"},{"key":"3193_CR64","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A.M., Brown-Frandsen, K., Colhoun, H.M., Deanfield, J., Emerson, S.S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G.K., Kahn, S.E., Kushner, R.F., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389, 2221\u20132232.","journal-title":"N Engl J Med"},{"key":"3193_CR65","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","volume":"68","author":"A Lonardo","year":"2018","unstructured":"Lonardo, A., Nascimbeni, F., Mantovani, A., and Targher, G. (2018). Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol 68, 335\u2013352.","journal-title":"J Hepatol"},{"key":"3193_CR66","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba, R., Friedman, S.L., and Shulman, G.I. (2021). Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537\u20132564.","journal-title":"Cell"},{"key":"3193_CR67","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba, R., Hartman, M.L., Lawitz, E.J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O.W., Tang, Y., et al. (2024). Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 391, 299\u2013310.","journal-title":"N Engl J Med"},{"key":"3193_CR68","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann, J.F.E., \u00d8rsted, D.D., Brown-Frandsen, K., Marso, S.P., Poulter, N.R., Rasmussen, S., Torn\u00f8e, K., Zinman, B., and Buse, J.B. (2017). Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377, 839\u2013848.","journal-title":"N Engl J Med"},{"key":"3193_CR69","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","volume":"30","author":"JFE Mann","year":"2024","unstructured":"Mann, J.F.E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D.M., Hadjadj, S., Gillard, P., G\u00f3rriz, J.L., et al. (2024). Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med 30, 2849\u20132856.","journal-title":"Nat Med"},{"key":"3193_CR70","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc17-1902","volume":"41","author":"A Mantovani","year":"2018","unstructured":"Mantovani, A., Byrne, C.D., Bonora, E., and Targher, G. (2018a). Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care 41, 372\u2013382.","journal-title":"Diabetes Care"},{"key":"3193_CR71","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K.E., Simon, T.G., Byrne, C.D., and Targher, G. (2021a). Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6, 903\u2013913.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3193_CR72","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/liv.14044","volume":"39","author":"A Mantovani","year":"2019","unstructured":"Mantovani, A., Dauriz, M., Sandri, D., Bonapace, S., Zoppini, G., Tilg, H., Byrne, C.D., and Targher, G. (2019). Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. Liver Int 39, 758\u2013769.","journal-title":"Liver Int"},{"key":"3193_CR73","doi-asserted-by":"publisher","first-page":"e16218","DOI":"10.1111\/liv.16218","volume":"45","author":"A Mantovani","year":"2025","unstructured":"Mantovani, A., Morandin, R., Sani, E., Fiorio, V., Shtembari, E., Bonapace, S., Petta, S., Polyzos, S.A., Byrne, C.D., and Targher, G. (2025). MASLD is associated with an increased long-term risk of atrial fibrillation: an updated systematic review and meta-analysis. Liver Int 45, e16218.","journal-title":"Liver Int"},{"key":"3193_CR74","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","volume":"71","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., Schattenberg, J. M., Tilg, H., Byrne, C.D., and Targher, G. (2022). Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut 71, 156\u2013162.","journal-title":"Gut"},{"key":"3193_CR75","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","volume":"70","author":"A Mantovani","year":"2021","unstructured":"Mantovani, A., Petracca, G., Beatrice, G., Tilg, H., Byrne, C.D., and Targher, G. (2021b). Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 70, 962\u2013969.","journal-title":"Gut"},{"key":"3193_CR76","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/gutjnl-2022-327672","volume":"72","author":"A Mantovani","year":"2023","unstructured":"Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., Bonapace, S., Rossi, A., Tilg, H., Byrne, C.D., and Targher, G. (2023). Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut 72, 372\u2013380.","journal-title":"Gut"},{"key":"3193_CR77","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","volume":"79","author":"A Mantovani","year":"2018","unstructured":"Mantovani, A., Zaza, G., Byrne, C.D., Lonardo, A., Zoppini, G., Bonora, E., and Targher, G. (2018b). Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism 79, 64\u201376.","journal-title":"Metabolism"},{"key":"3193_CR78","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jhep.2024.11.034","volume":"82","author":"T Marjot","year":"2025","unstructured":"Marjot, T. (2025). New evidence of cross-disease communication between heart and liver. J Hepatol 82, 541\u2013543.","journal-title":"J Hepatol"},{"key":"3193_CR79","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., J\u00f3dar, E., Leiter, L.A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M.L., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375, 1834\u20131844.","journal-title":"N Engl J Med"},{"key":"3193_CR80","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire, D.K., Marx, N., Mulvagh, S.L., Deanfield, J.E., Inzucchi, S.E., Pop-Busui, R., Mann, J.F.E., Emerson, S.S., Poulter, N.R., Engelmann, M.D.M., et al. (2025). Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med 392, 2001\u20132012.","journal-title":"N Engl J Med"},{"key":"3193_CR81","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jhep.2024.06.017","volume":"81","author":"JM Mucinski","year":"2024","unstructured":"Mucinski, J.M., Salvador, A.F., Moore, M.P., Fordham, T.M., Anderson, J.M., Shryack, G., Cunningham, R.P., Lastra, G., Gaballah, A.H., Diaz-Arias, A., et al. (2024). Histological improvements following energy restriction and exercise: the role of insulin resistance in resolution of MASH. J Hepatol 81, 781\u2013793.","journal-title":"J Hepatol"},{"key":"3193_CR82","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.2337\/dc15-1182","volume":"39","author":"G Musso","year":"2016","unstructured":"Musso, G., Cassader, M., Cohney, S., De Michieli, F., Pinach, S., Saba, F., and Gambino, R. (2016). Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities. Diabetes Care 39, 1830\u20131845.","journal-title":"Diabetes Care"},{"key":"3193_CR83","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.molmed.2015.08.005","volume":"21","author":"G Musso","year":"2015","unstructured":"Musso, G., Cassader, M., Cohney, S., Pinach, S., Saba, F., and Gambino, R. (2015). Emerging liver-kidney interactions in nonalcoholic fatty liver disease. Trends Mol Med 21, 645\u2013662.","journal-title":"Trends Mol Med"},{"key":"3193_CR84","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C.E., Neeland, I.J., Tuttle, K.R., Chow, S.L., Mathew, R.O., Khan, S.S., Coresh, J., Baker-Smith, C.M., Carnethon, M.R., Despr\u00e9s, J.P., et al. (2023a). A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation 148, 1636\u20131664.","journal-title":"Circulation"},{"key":"3193_CR85","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C.E., Rangaswami, J., Chow, S.L., Neeland, I.J., Tuttle, K.R., Khan, S.S., Coresh, J., Mathew, R.O., Baker-Smith, C.M., Carnethon, M.R., et al. (2023b). Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606\u20131635.","journal-title":"Circulation"},{"key":"3193_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","volume":"267","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls, S.J., Bhatt, D.L., Buse, J.B., Prato, S.D., Kahn, S.E., Lincoff, A.M., McGuire, D. K., Nauck, M.A., Nissen, S.E., Sattar, N., et al. (2024). Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J 267, 1\u201311.","journal-title":"Am Heart J"},{"key":"3193_CR87","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jhep.2025.05.013","volume":"83","author":"P Ochoa-Allemant","year":"2025","unstructured":"Ochoa-Allemant, P., Hubbard, R.A., Kaplan, D.E., and Serper, M. (2025). Cause-specific mortality in patients with steatotic liver disease in the United States. J Hepatol 83, 860\u2013869.","journal-title":"J Hepatol"},{"key":"3193_CR88","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jhep.2025.06.005","volume":"83","author":"JH Oh","year":"2025","unstructured":"Oh, J.H., Yoon, E.L., Park, H., Lee, S., Jo, A.J., Cho, S., Kwon, E., Nah, E.H., Lee, J.H., Park, J.H., et al. (2025). Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease. J Hepatol 83, 1256\u20131265.","journal-title":"J Hepatol"},{"key":"3193_CR89","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer, M., Zile, M.R., Kramer, C.M., Baum, S.J., Litwin, S.E., Menon, V., Ge, J., Weerakkody, G.J., Ou, Y., Bunck, M.C., et al. (2025). Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 392, 427\u2013437.","journal-title":"N Engl J Med"},{"key":"3193_CR90","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","volume":"84","author":"RE Pratley","year":"2024","unstructured":"Pratley, R.E., Tuttle, K.R., Rossing, P., Rasmussen, S., Perkovic, V., Nielsen, O.W., Mann, J.F.E., MacIsaac, R.J., Kosiborod, M.N., Kamenov, Z., et al. (2024). Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial. J Am Coll Cardiol 84, 1615\u20131628.","journal-title":"J Am Coll Cardiol"},{"key":"3193_CR91","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M.E., Lazarus, J.V., Ratziu, V., Francque, S.M., Sanyal, A.J., Kanwal, F., Romero, D., Abdelmalek, M.F., Anstee, Q.M., Arab, J.P., et al. (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 79, 1542\u20131556.","journal-title":"J Hepatol"},{"key":"3193_CR92","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1093\/eurheartj\/ehaf314","volume":"46","author":"S Romeo","year":"2025","unstructured":"Romeo, S., Vidal-Puig, A., Husain, M., Ahima, R., Arca, M., Bhatt, D.L., Diehl, A.M., Fontana, L., Foo, R., Fr\u00fchbeck, G., et al. (2025). Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement. Eur Heart J 46, 3685\u20133713.","journal-title":"Eur Heart J"},{"key":"3193_CR93","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cmet.2025.04.014","volume":"37","author":"JP Rose","year":"2025","unstructured":"Rose, J.P., Morgan, D.A., Sullivan, A.I., Fu, X., Inigo-Vollmer, M., Burgess, S.C., Meyerholz, D.K., Rahmouni, K., and Potthoff, M.J. (2025). FGF21 reverses MASH through coordinated actions on the CNS and liver. Cell Metab 37, 1515\u20131529.e6.","journal-title":"Cell Metab"},{"key":"3193_CR94","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jacbts.2021.07.010","volume":"6","author":"HM Salah","year":"2021","unstructured":"Salah, H.M., Pandey, A., Soloveva, A., Abdelmalek, M.F., Diehl, A.M., Moylan, C.A., Wegermann, K., Rao, V.N., Hernandez, A.F., Tedford, R.J., et al. (2021). Relationship of nonalcoholic fatty liver disease and heart failure with preserved ejection fraction. JACC Basic Transl Sci 6, 918\u2013932.","journal-title":"JACC Basic Transl Sci"},{"key":"3193_CR95","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal, A.J., Bedossa, P., Fraessdorf, M., Neff, G.W., Lawitz, E., Bugianesi, E., Anstee, Q.M., Hussain, S.A., Newsome, P.N., Ratziu, V., et al. (2024). A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med 391, 311\u2013319.","journal-title":"N Engl J Med"},{"key":"3193_CR96","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal, A.J., Newsome, P.N., Kliers, I., \u00d8stergaard, L.H., Long, M.T., Kj\u00e6r, M.S., Cali, A.M.G., Bugianesi, E., Rinella, M.E., Roden, M., et al. (2025). Phase 3 Trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 392, 2089\u20132099.","journal-title":"N Engl J Med"},{"key":"3193_CR97","doi-asserted-by":"publisher","unstructured":"Shi, Y., Zhou, R., Kim, S.U., Yip, T.C.F., Tsochatzis, E., Petta, S., Nakajima, A., Hagstr\u00f6m, H., Bugianesi, E., Chan, W.K., et al. (2025). Association between longitudinal weight change and clinical outcome in individuals with MASLD. Hepatology doi: https:\/\/doi.org\/10.1097\/hep.0000000000001557.","DOI":"10.1097\/hep.0000000000001557"},{"key":"3193_CR98","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/liv.15851","volume":"44","author":"C Siafarikas","year":"2024","unstructured":"Siafarikas, C., Kapelios, C.J., Papatheodoridi, M., Vlachogiannakos, J., Tentolouris, N., and Papatheodoridis, G. (2024). Sodium-glucose linked transporter 2 inhibitors in liver cirrhosis: beyond their antidiabetic use. Liver Int 44, 884\u2013893.","journal-title":"Liver Int"},{"key":"3193_CR99","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/dom.12651","volume":"18","author":"J Skov","year":"2016","unstructured":"Skov, J., Pedersen, M., Holst, J.J., Madsen, B., Goetze, J.P., Rittig, S., Jonassen, T., Fr\u00f8ki\u00e6r, J., Dejgaard, A., and Christiansen, J.S. (2016). Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab 18, 581\u2013589.","journal-title":"Diabetes Obes Metab"},{"key":"3193_CR100","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon, S.D., McMurray, J.J.V., Claggett, B., de Boer, R.A., DeMets, D., Hernandez, A. F., Inzucchi, S.E., Kosiborod, M.N., Lam, C.S.P., Martinez, F., et al. (2022). Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387, 1089\u20131098.","journal-title":"N Engl J Med"},{"key":"3193_CR101","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81, 492\u2013542.","journal-title":"J Hepatol"},{"key":"3193_CR102","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.2337\/dc21-2049","volume":"45","author":"Y Takeshita","year":"2022","unstructured":"Takeshita, Y., Honda, M., Harada, K., Kita, Y., Takata, N., Tsujiguchi, H., Tanaka, T., Goto, H., Nakano, Y., Iida, N., et al. (2022). Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care 45, 2064\u20132075.","journal-title":"Diabetes Care"},{"key":"3193_CR103","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher, G., Byrne, C.D., Lonardo, A., Zoppini, G., and Barbui, C. (2016). Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 65, 589\u2013600.","journal-title":"J Hepatol"},{"key":"3193_CR104","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher, G., Byrne, C.D., and Tilg, H. (2024). MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 73, 691\u2013702.","journal-title":"Gut"},{"key":"3193_CR105","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher, G., Tilg, H., and Byrne, C.D. (2021). Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 6, 578\u2013588.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3193_CR106","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher, G., Valenti, L., and Byrne, C.D. (2025). Metabolic dysfunction-associated steatotic liver disease. N Engl J Med 393, 683\u2013698.","journal-title":"N Engl J Med"},{"key":"3193_CR107","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/biom15020213","volume":"15","author":"N Theodorakis","year":"2025","unstructured":"Theodorakis, N., and Nikolaou, M. (2025). From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework. Biomolecules 15, 213.","journal-title":"Biomolecules"},{"key":"3193_CR108","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.cgh.2021.09.021","volume":"20","author":"JZK Toh","year":"2022","unstructured":"Toh, J.Z.K., Pan, X.H., Tay, P.W.L., Ng, C.H., Yong, J.N., Xiao, J., Koh, J.H., Tan, E.Y., Tan, E.X.X., Dan, Y.Y., et al. (2022). A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 20, 2462\u20132473.e10.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3193_CR109","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41581-021-00519-y","volume":"18","author":"TY Wang","year":"2022","unstructured":"Wang, T.Y., Wang, R.F., Bu, Z.Y., Targher, G., Byrne, C.D., Sun, D.Q., and Zheng, M. H. (2022). Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol 18, 259\u2013268.","journal-title":"Nat Rev Nephrol"},{"key":"3193_CR110","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., Silverman, M. G., Zelniker, T.A., Kuder, J.F., Murphy, S.A., et al. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380, 347\u2013357.","journal-title":"N Engl J Med"},{"key":"3193_CR111","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VWS Wong","year":"2023","unstructured":"Wong, V.W.S., Ekstedt, M., Wong, G.L.H., and Hagstr\u00f6m, H. (2023). Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol 79, 842\u2013852.","journal-title":"J Hepatol"},{"key":"3193_CR112","doi-asserted-by":"publisher","first-page":"2500099","DOI":"10.1080\/19490976.2025.2500099","volume":"17","author":"H Wu","year":"2025","unstructured":"Wu, H., Chen, J., Guo, S., Deng, J., Zhou, Z., Zhang, X., Qi, T.T., Yu, F., and Yang, Q. (2025). Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease. Gut Microbes 17, 2500099.","journal-title":"Gut Microbes"},{"key":"3193_CR113","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.cmet.2024.04.020","volume":"36","author":"W Xie","year":"2024","unstructured":"Xie, W., Gan, J., Zhou, X., Tian, H., Pan, X., Liu, W., Li, X., Du, J., Xu, A., Zheng, M., et al. (2024). Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periostin. Cell Metab 36, 1269\u20131286.e9.","journal-title":"Cell Metab"},{"key":"3193_CR114","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1007\/s11427-025-2948-y","volume":"68","author":"S Xu","year":"2025","unstructured":"Xu, S., Liu, Y., Zhu, M., Chen, K., Xu, F., and Liu, Y. (2025). Global burden of atherosclerotic cardiovascular disease attributed to lifestyle and metabolic risks. Sci China Life Sci 68, 2739\u20132754.","journal-title":"Sci China Life Sci"},{"key":"3193_CR115","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.7150\/thno.106597","volume":"15","author":"M Yan","year":"2025","unstructured":"Yan, M., Cui, Y., and Xiang, Q. (2025). Metabolism of hepatic stellate cells in chronic liver diseases: emerging molecular and therapeutic interventions. Theranostics 15, 1715\u20131740.","journal-title":"Theranostics"},{"key":"3193_CR116","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi, Z.M., Kalligeros, M., and Henry, L. (2025). Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol 31, S32\u2013S50.","journal-title":"Clin Mol Hepatol"},{"key":"3193_CR117","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","volume":"143","author":"F Zannad","year":"2021","unstructured":"Zannad, F., Ferreira, J.P., Pocock, S.J., Zeller, C., Anker, S.D., Butler, J., Filippatos, G., Hauske, S.J., Brueckmann, M., Pfarr, E., et al. (2021). Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced. Circulation 143, 310\u2013321.","journal-title":"Circulation"},{"key":"3193_CR118","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/joim.13793","volume":"296","author":"F Zannad","year":"2024","unstructured":"Zannad, F., Sanyal, A.J., Butler, J., Ferreira, J.P., Girerd, N., Miller, V., Pandey, A., Parikh, C.R., Ratziu, V., Younossi, Z.M., et al. (2024a). MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials. J Intern Med 296, 24\u201338.","journal-title":"J Intern Med"},{"key":"3193_CR119","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1038\/s41591-024-03223-z","volume":"30","author":"F Zannad","year":"2024","unstructured":"Zannad, F., Sanyal, A.J., Butler, J., Miller, V., and Harrison, S.A. (2024b). Integrating liver endpoints in clinical trials of cardiovascular and kidney disease. Nat Med 30, 2423\u20132431.","journal-title":"Nat Med"},{"key":"3193_CR120","doi-asserted-by":"publisher","first-page":"155999","DOI":"10.1016\/j.metabol.2024.155999","volume":"160","author":"H Zhang","year":"2024","unstructured":"Zhang, H., Zhou, X.D., Shapiro, M.D., Lip, G.Y.H., Tilg, H., Valenti, L., Somers, V.K., Byrne, C.D., Targher, G., Yang, W., et al. (2024). Global burden of metabolic diseases, 1990\u20132021. Metabolism 160, 155999.","journal-title":"Metabolism"},{"key":"3193_CR121","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12933-022-01697-0","volume":"21","author":"XD Zhou","year":"2022","unstructured":"Zhou, X.D., Cai, J., Targher, G., Byrne, C.D., Shapiro, M.D., Sung, K.C., Somers, V.K., Chahal, C.A.A., George, J., Chen, L.L., et al. (2022). Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol 21, 270.","journal-title":"Cardiovasc Diabetol"},{"key":"3193_CR122","doi-asserted-by":"publisher","unstructured":"Zhou, X.D., Chen, Q.F., Fan, Q.Y., Kim, S.U., Yip, T.C.F., Petta, S., Nakajima, A., Tsochatzis, E., Boursier, J., Bugianesi, E., et al. (2025a). Cardiovascular-Kidney-Metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD. Hepatology doi: https:\/\/doi.org\/10.1097\/hep.0000000000001645.","DOI":"10.1097\/hep.0000000000001645"},{"key":"3193_CR123","doi-asserted-by":"publisher","unstructured":"Zhou, X.D., Chen, Q.F., Kim, S.U., Cheuk-Fung Yip, T., Petta, S., Nakajima, A., Tsochatzis, E., Boursier, J., Bugianesi, E., Hagstr\u00f6m, H., et al. (2025b). Long-term glycemic control and the risk of liver stiffness progression and liver-related events in MASLD. Clin Gastroenterol Hepatol doi: https:\/\/doi.org\/10.1016\/j.cgh.2025.10.003.","DOI":"10.1016\/j.cgh.2025.10.003"},{"key":"3193_CR124","doi-asserted-by":"publisher","first-page":"e032997","DOI":"10.1161\/JAHA.123.032997","volume":"13","author":"X Zhou","year":"2024","unstructured":"Zhou, X., Chen, Q., Targher, G., Byrne, C.D., Shapiro, M.D., Tian, N., Xiao, T., Sung, K., Lip, G.Y.H., and Zheng, M. (2024a). High-sensitivity C-reactive protein is associated with heart failure hospitalization in patients with metabolic dysfunction-associated fatty liver disease and normal left ventricular ejection fraction undergoing coronary angiography. J Am Heart Assoc 13, e032997.","journal-title":"J Am Heart Assoc"},{"key":"3193_CR125","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","volume":"73","author":"XD Zhou","year":"2024","unstructured":"Zhou, X.D., Kim, S.U., Yip, T.C.F., Petta, S., Nakajima, A., Tsochatzis, E., Boursier, J., Bugianesi, E., Hagstr\u00f6m, H., Chan, W.K., et al. (2024b). Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease. Gut 73, 1883\u20131892.","journal-title":"Gut"},{"key":"3193_CR126","doi-asserted-by":"publisher","unstructured":"Zhou, X.D., Li, Y.T., Kim, S.U., Yip, T.C.F., Petta, S., Nakajima, A., Tsochatzis, E., Shi, J., Chan, W.K., Boursier, J., et al. (2025c). Longitudinal changes in fibrosis markers: monitoring stiffness\/fibrosis progression and prognostic outcomes in MASLD. Clin Gastroenterol Hepatol doi: https:\/\/doi.org\/10.1016\/j.cgh.2025.07.011.","DOI":"10.1016\/j.cgh.2025.07.011"},{"key":"3193_CR127","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jhep.2025.08.017","volume":"84","author":"XD Zhou","year":"2026","unstructured":"Zhou, X.D., Lian, L.Y., Chen, Q.F., Kim, S.U., Cheuk-Fung Yip, T., Petta, S., Nakajima, A., Tsochatzis, E., Shi, J., Chan, W.K., et al. (2026a). Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD. J Hepatol 84, 254\u2013265.","journal-title":"J Hepatol"},{"key":"3193_CR128","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.scib.2024.01.006","volume":"69","author":"XD Zhou","year":"2024","unstructured":"Zhou, X.D., Lip, G.Y.H., and Zheng, M.H. (2024c). From HFpEF to \u201cmetabolic (dysfunction)-associated HFpEF\u201d: time to act. Sci Bull 69, 850\u2013852.","journal-title":"Sci Bull"},{"key":"3193_CR129","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/j.jhep.2024.03.039","volume":"81","author":"XD Zhou","year":"2024","unstructured":"Zhou, X.D., Lonardo, A., Pan, C.Q., Shapiro, M.D., and Zheng, M.H. (2024d). Clinical features and long-term outcomes of patients diagnosed with MASLD, MAFLD, or both. J Hepatol 81, e157\u2013e159.","journal-title":"J Hepatol"},{"key":"3193_CR130","doi-asserted-by":"publisher","first-page":"101645","DOI":"10.1016\/j.jhepr.2025.101645","volume":"8","author":"XD Zhou","year":"2026","unstructured":"Zhou, X.D., Song, S.J., Guo, C.Y., Chen, Q.F., Lai-Hung Wong, G., Ye, T.R., Bee Goh, G. B., Bee, Y.M., Lian, L.Y., Cheuk-Fung Yip, T., et al. (2026b). Validation of a data-driven clustering model for MASLD: evidence from three large-scale Asian cohorts. JHEP Rep 8, 101645.","journal-title":"JHEP Rep"},{"key":"3193_CR131","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CP9.0000000000000106","volume":"9","author":"XD Zhou","year":"2024","unstructured":"Zhou, X.D., Targher, G., Byrne, C.D., Shapiro, M.D., Chen, L.L., and Zheng, M.H. (2024e). Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology. Cardiol Plus 9, 275\u2013282.","journal-title":"Cardiol Plus"},{"key":"3193_CR132","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","volume":"17","author":"XD Zhou","year":"2023","unstructured":"Zhou, X.D., Targher, G., Byrne, C.D., Somers, V., Kim, S.U., Chahal, C.A.A., Wong, V. W.S., Cai, J., Shapiro, M.D., Eslam, M., et al. (2023). An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int 17, 773\u2013791.","journal-title":"Hepatol Int"},{"key":"3193_CR133","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3350\/cmh.2024.1131","volume":"31","author":"XD Zhou","year":"2025","unstructured":"Zhou, X.D., Yip, T.C.F., Huang, D.Q., Muthiah, M.D., Noureddin, M., and Zheng, M.H. (2025d). Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease. Clin Mol Hepatol 31, 620\u2013624.","journal-title":"Clin Mol Hepatol"},{"key":"3193_CR134","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41569-025-01199-y","volume":"22","author":"XD Zhou","year":"2025","unstructured":"Zhou, X.D., and Zheng, M.H. (2025). Cardiovascular-kidney-metabolic syndrome and MASLD: integrating medical perspectives. Nat Rev Cardiol 22, 843.","journal-title":"Nat Rev Cardiol"},{"key":"3193_CR135","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41575-025-01144-x","volume":"23","author":"XD Zhou","year":"2026","unstructured":"Zhou, X.D., and Zheng, M.H. (2026). Heart-liver co-management in MASLD: from concept to clinical practice. Nat Rev Gastroenterol Hepatol 23, 117\u2013118.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3193_CR136","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/hep4.1155","volume":"2","author":"Y Zhou","year":"2018","unstructured":"Zhou, Y., Zhou, X., Wu, S., Fan, D., Van Poucke, S., Chen, Y., Fu, S., and Zheng, M. (2018). Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. Hepatol Commun 2, 376\u2013392.","journal-title":"Hepatol Commun"},{"key":"3193_CR137","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373, 2117\u20132128.","journal-title":"N Engl J Med"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3193-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-025-3193-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3193-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T09:03:04Z","timestamp":1780736584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-025-3193-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":137,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3193"],"URL":"https:\/\/doi.org\/10.1007\/s11427-025-3193-9","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}